Skip to main content
Premium Trial:

Request an Annual Quote

Microbiome Firms Enterome, Second Genome Close Financing Rounds

NEW YORK (GenomeWeb) – Microbiome firms Enterome Bioscience and Second Genome today announced that they each have closed financing rounds worth €14.5 million ($16.5 million) and $42.6 million, respectively.

Paris-based Enterome completed a Series C financing round that it said would provide it with additional financing to develop its pipeline of microbiome-related drugs and diagnostics.

The round was led by existing investors Seventure and Lundbeckfond Ventures, and included new investor Nestlé Health Science. Additional terms of the financing were not disclosed.

The funds will be used to support the advancement of Enterome's inflammatory bowel disease drug EB8018, a small molecule designed to block adherent invasive Escherichia coli in the gut, into initial clinical testing. The financing will also help the company further develop diagnostics in IBD and other microbiome-related disorders.

In late 2014, Enterome formed a partnership with biotech firm AbbVie to create molecular diagnostic tools to monitor the gut microbiome in patients with Crohn's disease and related conditions. Earlier that year, the company announced partnerships with the Mayo Clinic and Synthetic Biologics to develop microbiome-based tests. 

Second Genome, meanwhile, finalized a Series B round co-led by Pfizer Venture Investments and Roche Venture Fund. The round also included new investors Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, and Mayo Clinic, as well as existing investors Advanced Technology Ventures, Morgenthaler Ventures, Seraph Group, and individual investor Matthew Winkler.

Second Genome said the funding would be used to expand its microbiome drug-discovery platform in indications associated with barrier function, insulin sensitivity, and immune regulation. The money will also be used to conduct human proof-of-concept studies of the South San Francisco-based firm's small-molecule treatment for ulcerative colitis-associated pain and inflammation SGM-1019.

About a year ago, Second Genome partnered with the Alimentary Pharmabiotic Centre Microbiome Institute at University College Cork to develop therapies to prevent and treat IBD. The company also has formed alliances with the Mayo Clinic, Pfizer, and Johnson & Johnson's Janssen Biotech.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.